Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ardelyx, Inc. - Common Stock (NQ:ARDX)

5.010 +0.050 (+1.01%)
Official Closing Price Updated: 4:15 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ardelyx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
3 Groundbreaking Biotech Stocks to Invest in Now
These are several biotech companies for investors seeking unique opportunities for great returns within the industry. 
Via InvestorPlace
7 Small-Cap Stocks to Buy for Big Gains in 2024
Small-cap stocks are a great way to diversify your portfolio and set yourself up for some potentially dynamic gains. 
Via InvestorPlace
3 mid-caps under $20 that Wall Street loves
MarketBeat's Stock Screener tool helped identify these three mid-cap stocks - with very bullish Wall Street sentiment - that are currently under $20 per share 
Via MarketBeat
Topics Artificial Intelligence Economy
Wedbush Maintains Outperform Rating for Ardelyx: Here's What You Need To Know
 
Via Benzinga
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Why Ardelyx Stock Is Climbing Higher
 
Via Benzinga
What Analysts Are Saying About Ardelyx Stock
 
Via Benzinga
The 3 Best Under-$10 Stocks to Buy in January 2024
These are a few companies for investors looking for inexpensive options that still offer great earnings potential. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Nvidia, Boeing, Ardelyx, Crocs, Tesla: Why These 5 Stocks Are On Investors' Radars Today
 
Via Benzinga
What's Going On With Ardelyx Stock?
Ardelyx, Inc. (NASDAQ: ARDX) shares are trading higher Monday after the company provided a strategic business update. 
Via Benzinga
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
From Ardelyx, Inc.
Via GlobeNewswire
The Latest Analyst Ratings for Ardelyx
 
Via Benzinga
Why Ardelyx Stock Soared Today
Ardelyx delivered a strong quarter thanks to solid demand for its first FDA-approved product. Here's what investors need to know. 
Via The Motley Fool
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on... 
Via Benzinga
Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
Live event and webcast scheduled for 7:00 p.m. ET / 4:00 p.m. PT 
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
Positive News For Skin Health: Aldeyra Therapeutics' ADX-629 Achieves Key Milestones in Atopic Dermatitis Study
Aldeyra Therapeutics Inc (NASDAQ: ALDX) released topline results from a Phase 2 clinical trial of ADX-629, an investigational RASP modulator, in  
Via Benzinga
Patient Demand Drives Ardelyx's Constipation Drug Success Amid IBS-C Treatment Gap, Says Analyst
Raymond James initiated coverage of Ardelyx Inc (NASDAQ: ARDX), noting the company's two early-stage launches underway for the same molecule with differentiated pricing: 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
3 Short-Squeeze Stocks Ready for a Year-End Rally
These are a few companies that have seen considerable gains this year that still have a large percentage of short interest. 
Via InvestorPlace
Ardelyx, Inc. Reports Employment Inducement Grants
From Ardelyx, Inc.
Via GlobeNewswire
7 Penny Stocks You’ll Regret Not Buying Soon: November 2023
Unlock robust upside potential by wagering on these top penny stocks to buy in a volatile market at this time. 
Via InvestorPlace
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Announces Departure of Board Member
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx to Participate at the Jefferies London Healthcare Conference
From Ardelyx, Inc.
Via GlobeNewswire
5 OTC Stocks With The Potential To Explode In 2024
Investors who are ready to dive into the OTC pool have more options than ever, both with the number of stocks to choose from and available investing platforms. 
Via Benzinga
Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
From Ardelyx, Inc.
Via GlobeNewswire
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
From Ardelyx, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.